What is Baqsimi?
Baqsimi is a ready-to-use, intranasal glucagon powder (3 mg dose) approved for treating severe hypoglycemia in people with diabetes aged 1 year and older, offering a needle-free, single-step emergency treatment that does not require reconstitution or inhalation. 1
Mechanism and Formulation
Baqsimi contains glucagon as a white nasal powder delivered through a single-use intranasal device. The medication is absorbed passively through the nasal mucosa—you do not need to inhale it for it to work 1. Each device contains one 3 mg dose of glucagon with betadex and dodecylphosphocholine as excipients, and it remains effective even if the patient has a cold or is taking cold medicine 1.
Clinical Indication
Baqsimi is specifically indicated for severe hypoglycemia—defined as hypoglycemic episodes where the person is unable or unwilling to consume oral carbohydrates due to confusion, loss of consciousness, or seizures 2, 1. This represents a medical emergency requiring immediate intervention.
Why Baqsimi Matters: The Problem It Solves
Traditional injectable glucagon required a complex multi-step reconstitution process (mixing powder with liquid) before injection, which frequently resulted in:
- Failure to administer the full therapeutic dose by untrained and even trained caregivers
- Delays in treatment during high-stress emergency situations
- Fear and reluctance to use injectable formulations 3
Current guidelines strongly recommend glucagon preparations that do not require reconstitution (like Baqsimi) over traditional formulations because ease of administration is critical when family members or bystanders must act quickly during a severe hypoglycemic emergency 3.
Administration
The administration is remarkably simple:
- Insert the tip into one nostril and press the plunger completely until the green line disappears
- The entire dose is delivered in one actuation
- Call emergency services immediately after administration 1
- When the person responds, provide oral carbohydrates (fast-acting like juice, then long-acting like crackers with peanut butter) 1
- If no response after 15 minutes, a second 3 mg dose may be given from a new device while waiting for emergency help 1
In simulation studies, caregivers administered intranasal glucagon within 1 minute versus 1.3-5 minutes for intramuscular glucagon 4.
Efficacy
Clinical trials demonstrate that Baqsimi achieves treatment success (blood glucose increase ≥20 mg/dL) in essentially 100% of patients within 15-20 minutes, comparable to injectable glucagon 1, 5. In pediatric patients aged 4 to <17 years, mean time to glucose increase of ≥20 mg/dL ranged from 10.8 to 14.2 minutes 1. Studies in children aged 1 to <4 years showed 100% achieved glucose increase ≥20 mg/dL within 30 minutes 1.
Notably, Baqsimi achieves a lower mean maximum blood glucose (168 mg/dL) compared to other ready-to-use formulations (220 mg/dL for Gvoke, 190 mg/dL for Zegalogue), which may facilitate faster return to normal glucose levels 5.
Who Should Have Baqsimi
All individuals treated with insulin or at high risk for severe hypoglycemia should be prescribed glucagon 2. This includes:
- Anyone with type 1 diabetes on insulin
- Type 2 diabetes patients on insulin or insulin secretagogues (sulfonylureas, meglitinides)
- Those with impaired hypoglycemia awareness
- History of severe hypoglycemia
- Patients with long-standing diabetes 2, 3
Clinicians should routinely review glucagon access at every visit, as appropriate glucagon prescribing remains very low in practice—only 4.4% in one recent study of high-risk patients 2, 6.
Contraindications
Do not use Baqsimi in patients with:
- Pheochromocytoma (may cause dangerous catecholamine release and severe hypertension)
- Insulinoma (may paradoxically worsen hypoglycemia by stimulating excessive insulin release)
- Known hypersensitivity to glucagon 1
Important Limitations
Baqsimi only works if the patient has adequate hepatic glycogen stores. It will be ineffective in:
- Prolonged starvation or fasting
- Adrenal insufficiency
- Chronic hypoglycemia states
These patients require intravenous glucose instead 1.
Adverse Effects
Most common side effects (≥10%):
- Nausea and vomiting (typical for all glucagon formulations)
- Upper respiratory tract irritation (rhinorrhea, nasal discomfort, congestion, cough, epistaxis)
- Watery eyes, eye redness
- Itchy nose, throat, and eyes 1
Nasal and ophthalmologic adverse events occur more frequently with intranasal formulations compared to injectable glucagon, but serious adverse events are rare 3.
Storage and Practical Considerations
- Store at temperatures up to 86°F (30°C) in the shrink-wrapped tube
- Keep in the tube until ready to use—if opened prematurely, moisture exposure may compromise effectiveness
- Each device is single-use only and cannot be reused
- Check expiration dates regularly and replace as needed 1
Caregiver Education is Critical
Family members, roommates, school personnel, childcare providers, and coworkers must be educated on:
- Where Baqsimi is kept
- How to recognize severe hypoglycemia
- When and how to administer it
- Never give insulin to someone with hypoglycemia 2
The ease of use makes Baqsimi particularly valuable for pediatric populations and situations where caregivers may be uncomfortable with injections 3, 7.